Search
Research
OMIP-100: A flow cytometry panel to investigate human neutrophil subsetsThis 14-color, 13-antibody optimized multicolor immunofluorescence panel (OMIP) was designed for deep profiling of neutrophil subsets in various types of human samples to contextualize neutrophil plasticity in a range of healthy and diseased states. Markers present in the OMIP allow the profiling of neutrophil subsets associated with ontogeny, migration, phagocytosis capacity, granule release, and immune modulation.
Research
Bronchial brushings for investigating airway inflammation and remodellingAsthma is the commonest medical cause for hospital admission for children in Australia, affects more than 300 million people worldwide, and is incurable...
Research
Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storageInterleukin-8 (IL-8) and neutrophil elastase (NE) are commonly measured markers of inflammation in bronchoalveolar lavage (BAL) fluid from patients with cystic
Research
Improved diagnosis, treatment and prevention of recurrent tonsillitisStrep A causes over 775 million infections each year world-wide, including over 615 million cases of tonsil infection (Strep throat).
Research
BEAT-CF: Bayesian Evidence-Adaptive Tool to optimise management of Cystic FibrosisAn innovative response-adaptive approach to driving improvements in health outcomes, applied to cystic fibrosis.
Research
Developing a novel therapeutic pipeline for antibiotic resistant bacterial lung infection in children: investigating and assessing the potential phage therapyAntimicrobial resistance is a global health crisis, which has accelerated due to the overuse of antibiotics.
Research
A Small Device May Deliver King-Sized Solutions for Patients With an Exacerbation of Cystic FibrosisThe aim is to examine whether using a portable spring-infusor device to deliver antibiotics compared with a standard infusion pump (SIP) translated to (i) improve health outcomes, (ii) reduce the length of stay (LoS), and (iii) reduce cost for treatment of exacerbations of cystic fibrosis.
Research
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialRepurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries.
Research
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytesImmune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response.
Research
Innate inflammatory responses of pediatric cystic fibrosis airway epithelial cells: Effects of nonviral and viral stimulationThere is controversy regarding whether cystic fibrosis (CF) airway epithelial cells (AECs) are intrinsically proinflammatory.